Abstracts tagged "meta-analysis and radiography"

Abstract Number: 1654 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate-Naïve Patients with Rheumatoid Arthritis
Roy Fleischmann¹, Janet E. Pope², Vanita Tongbram³, Derek Tang⁴, James Chung⁵, David Collier⁵, Shilpa Urs³, Kerigo Ndirangu³, George A. Wells⁶ and Ronald F. van Vollenhoven⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Western Ontario, London, ON, Canada, ³ICON Plc., Morristown, NJ, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁷Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Several published randomized head-to-head trials in rheumatoid arthritis (RA) have compared TNFi-MTX with triple therapy (MTX + hydroxychloroquine + sulfasalazine) in MTX-naive patients (MTX-Ns)…
Abstract Number: 1642 • 2015 ACR/ARHP Annual Meeting
A Systematic Review and Network Meta-Analysis on the Efficacy of Tumor Necrosis Factor Inhibitor-Methotrexate Combination Therapy Versus Triple Therapy in Methotrexate Inadequate Responders with Rheumatoid Arthritis
Roy Fleischmann¹, Janet E. Pope², Vanita Tongbram³, Derek Tang⁴, James Chung⁵, David Collier⁵, Shilpa Urs³, Kerigo Ndirangu³, George A. Wells⁶ and Ronald F. van Vollenhoven⁷, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²University of Western Ontario, London, ON, Canada, ³ICON Plc., Morristown, NJ, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada, ⁷Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Previously published rheumatoid arthritis (RA) trials in which TNFi-MTX and triple therapy (MTX + hydroxychloroquine + sulfasalazine) were included as treatment arms in MTX…
Abstract Number: 186 • 2014 ACR/ARHP Annual Meeting
The Association Between Low Back Pain and Radiographic Features: A Systematic Review with Meta-Analysis
Joachim Raastad¹, Michael Reiman², Remy Coeytaux², Leila Ledbetter³ and Adam P. Goode², ¹Physical Therapy, Bergen University College, Bergen, Norway, ²Community and Family Medicine, Duke University, Durham, NC, ³Medical Center Library, Duke University, Durahm, NC
Background/Purpose: Low back pain (LBP) is a prevalent condition. Plain film radiography is a commonly used imaging technique for this condition. Radiographic features (RF) such…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.